Abstract
The autoantibody-based EarlyCDT®-Lung test is advertised as a pre-screening test that can be used to identify individuals at high risk of lung cancer who may benefit from LDCT screening. The test is increasingly used to inform eligibility for lung cancer screening in practice, but data from the general population on its ability to predict incident lung cancer is limited. We aimed to evaluate the performance of the EarlyCDT®-Lung test for predicting incident lung cancer in the general population, and compare it with a preliminary protein-based risk model.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
